150 related articles for article (PubMed ID: 22987257)
1. Effects of low molecular weight heparins and unfractionated heparin on viability of human umbilical vein endothelial cells.
Guler T; Polat ZA; Yayci E; Atacag T; Cetin A
Arch Gynecol Obstet; 2013 Feb; 287(2):217-22. PubMed ID: 22987257
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic activities of bemiparin sodium, enoxaparin sodium, nadroparin calcium and tinzaparin sodium.
Dogan OT; Polat ZA; Karahan O; Epozturk K; Altun A; Akkurt I; Cetin A
Thromb Res; 2011 Oct; 128(4):e29-32. PubMed ID: 21605890
[TBL] [Abstract][Full Text] [Related]
3. Influence of low molecular weight heparin preparations on human internal thoracic artery contraction.
Buzun L; Kleszczewski T; Kostrzewska A; Lisowski P; Oleksza P; Jackowski R; Pedzińska A; Hirnle T
Eur J Cardiothorac Surg; 2004 Nov; 26(5):951-5. PubMed ID: 15519188
[TBL] [Abstract][Full Text] [Related]
4. Effects of heparin and low-molecular-weight heparins on bone mechanical properties in rats.
Folwarczna J; Janiec W; Sliwiński L
Thromb Haemost; 2004 Nov; 92(5):940-6. PubMed ID: 15543319
[TBL] [Abstract][Full Text] [Related]
5. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs.
Jun L; Arnout J; Vanhove P; Dol F; Lormeau JC; Herbert JM; Collen D; Van de Werf F
Coron Artery Dis; 1995 Mar; 6(3):257-63. PubMed ID: 7788040
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of fondaparinux and bemiparin on angiogenic and vasculogenesis-like processes.
Da Pozzo E; Barsotti MC; Bendinelli S; Martelli A; Calderone V; Balbarini A; Martini C; Di Stefano R
Thromb Res; 2012 Sep; 130(3):e113-22. PubMed ID: 22497885
[TBL] [Abstract][Full Text] [Related]
7. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous factor Xa and IIa formation and on thrombelastometry profiles.
Cvirn G; Wagner T; Juergens G; Koestenberger M
Blood Coagul Fibrinolysis; 2009 Jan; 20(1):71-7. PubMed ID: 20339323
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers.
Antonijoan RM; Rico S; Martínez-González J; Borrell M; Valcarcel D; Fontcuberta J; Barbanoj MJ
Int J Clin Pharmacol Ther; 2009 Dec; 47(12):726-32. PubMed ID: 19954711
[TBL] [Abstract][Full Text] [Related]
9. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood.
Cvirn G; Hoerl G; Tafeit E; Heinl N; Wodrig K; Wagner T; Koestenberger M; Juergens G
Neonatology; 2011; 100(1):23-31. PubMed ID: 21150227
[TBL] [Abstract][Full Text] [Related]
10. Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells.
Martinez-Sales V; Vila V; Réganon E; Oms JG; Aznar J
Haematologica; 2003 Jun; 88(6):694-9. PubMed ID: 12801846
[TBL] [Abstract][Full Text] [Related]
11. High and low molecular weight heparins do not modify red blood cell aggregability in vitro.
Martínez M; Vaya A; López-Camacho C; Coll-Sangrona E; Mira Y; Aznar J
Clin Hemorheol Microcirc; 2000; 23(1):67-70. PubMed ID: 11214715
[TBL] [Abstract][Full Text] [Related]
12. Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes.
Vila V; Martínez-Sales V; Réganon E; Peris E; Perez F; Ruano M; Aznar J
Haematologica; 2001 Jul; 86(7):729-34. PubMed ID: 11454528
[TBL] [Abstract][Full Text] [Related]
13. In vitro anticoagulation monitoring of low-molecular-weight heparin.
Wang JQ; Shi XB; Yang JG; Hu DY
Chin Med J (Engl); 2009 May; 122(10):1199-202. PubMed ID: 19493471
[TBL] [Abstract][Full Text] [Related]
14. Osteoblast growth inhibition by unfractionated heparin and by low molecular weight heparins: an in-vitro investigation.
Kock HJ; Handschin AE
Clin Appl Thromb Hemost; 2002 Jul; 8(3):251-5. PubMed ID: 12361203
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte growth factor/activin A/follistatin system activation during hemodialysis with different low molecular weight heparins.
Rydzewska-Rosołowska A; Borawski J; Myśliwiec M
Ren Fail; 2009; 31(9):791-7. PubMed ID: 19925286
[TBL] [Abstract][Full Text] [Related]
16. Bemiparin and fluid flow modulate the expression, activity and release of tissue factor pathway inhibitor in human endothelial cells in vitro.
Westmuckett AD; Kakkar VV; Hamuro T; Lupu F; Lupu C
Thromb Haemost; 2001 Dec; 86(6):1547-54. PubMed ID: 11776326
[TBL] [Abstract][Full Text] [Related]
17. A study of unfractionated and low molecular weight heparins in a model of cholestatic liver injury in the rat.
Abdel-Salam OM; Baiuomy AR; Ameen A; Hassan NS
Pharmacol Res; 2005 Jan; 51(1):59-67. PubMed ID: 15519536
[TBL] [Abstract][Full Text] [Related]
18. Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin.
Marchetti M; Vignoli A; Russo L; Balducci D; Pagnoncelli M; Barbui T; Falanga A
Thromb Res; 2008; 121(5):637-45. PubMed ID: 17692905
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).
Collignon F; Frydman A; Caplain H; Ozoux ML; Le Roux Y; Bouthier J; Thébault JJ
Thromb Haemost; 1995 Apr; 73(4):630-40. PubMed ID: 7495071
[TBL] [Abstract][Full Text] [Related]
20. Different effects of enoxaparin, nadroparin, and dalteparin on plasma TFPI during hemodialysis: a prospective crossover randomized study.
Naumnik B; Rydzewska-Rosołowska A; Myśliwiec M
Clin Appl Thromb Hemost; 2011 Oct; 17(5):480-6. PubMed ID: 20682597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
